Amgen (AMGN) Non-Current Assets (2009 - 2026)
Amgen's quarterly Non-Current Assets came in at $61.0 billion in Q1 2026, down 2.26% year-on-year from $62.4 billion in Q1 2025, and down 0.81% quarter-over-quarter from $61.5 billion in Q4 2025.
Amgen has reported Non-Current Assets for 18 years, with the latest figure at $61.0 billion in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets fell 2.26% year-over-year to $61.0 billion; the trailing twelve-month figure through Mar 2026 stood at $246.0 billion (down 2.8% YoY), and the FY2025 full-year result was $61.5 billion, down 2.04% from the prior year.
- Non-Current Assets for Q1 2026 stood at $61.0 billion, down from $61.5 billion in the prior quarter.
- The five-year high for Non-Current Assets was $66.8 billion in Q4 2023, with the low at $39.6 billion in Q3 2022.
- Average Non-Current Assets over 5 years is $54.3 billion, with a median of $61.2 billion recorded in 2025.
- Year-over-year, Non-Current Assets surged 55.64% in 2023 and retreated 6.01% in 2024.
- Tracing AMGN's Non-Current Assets over 5 years: stood at $42.9 billion in 2022, then surged by 55.64% to $66.8 billion in 2023, then decreased by 6.01% to $62.8 billion in 2024, then retreated by 2.04% to $61.5 billion in 2025, then decreased by 0.81% to $61.0 billion in 2026.
- The last three Non-Current Assets figures came in at $61.0 billion (Q1 2026), $61.5 billion (Q4 2025), and $62.3 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 61.74 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 141.72 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 102.93 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 125.00 Mn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 61.03 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 37.64 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 165.18 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 59.27 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 58.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 61.03 Bn |
| Dec 31, 2025 | 61.53 Bn |
| Sep 30, 2025 | 62.26 Bn |
| Jun 30, 2025 | 61.16 Bn |
| Mar 31, 2025 | 62.44 Bn |
| Dec 31, 2024 | 62.81 Bn |
| Sep 30, 2024 | 64.12 Bn |
| Jun 30, 2024 | 63.70 Bn |
| Mar 31, 2024 | 64.95 Bn |
| Dec 31, 2023 | 66.82 Bn |
| Sep 30, 2023 | 42.06 Bn |
| Jun 30, 2023 | 42.89 Bn |
| Mar 31, 2023 | 44.02 Bn |
| Dec 31, 2022 | 42.94 Bn |
| Sep 30, 2022 | 39.64 Bn |
| Jun 30, 2022 | 39.97 Bn |
| Mar 31, 2022 | 40.68 Bn |
| Dec 31, 2021 | 41.78 Bn |
| Sep 30, 2021 | 40.61 Bn |
| Jun 30, 2021 | 40.67 Bn |
| Mar 31, 2021 | 41.24 Bn |
| Dec 31, 2020 | 41.80 Bn |
| Sep 30, 2020 | 41.98 Bn |
| Jun 30, 2020 | 42.12 Bn |
| Mar 31, 2020 | 42.86 Bn |
| Dec 31, 2019 | 41.27 Bn |
| Sep 30, 2019 | 28.48 Bn |
| Jun 30, 2019 | 28.63 Bn |
| Mar 31, 2019 | 28.85 Bn |
| Dec 31, 2018 | 28.80 Bn |
| Sep 30, 2018 | 29.01 Bn |
| Jun 30, 2018 | 29.71 Bn |
| Mar 31, 2018 | 30.48 Bn |
| Dec 31, 2017 | 30.48 Bn |
| Sep 30, 2017 | 30.58 Bn |
| Jun 30, 2017 | 31.15 Bn |
| Mar 31, 2017 | 31.41 Bn |
| Dec 31, 2016 | 31.62 Bn |
| Sep 30, 2016 | 32.31 Bn |
| Jun 30, 2016 | 32.52 Bn |
| Mar 31, 2016 | 32.91 Bn |
| Dec 31, 2015 | 32.93 Bn |
| Sep 30, 2015 | 33.03 Bn |
| Jun 30, 2015 | 33.47 Bn |
| Mar 31, 2015 | 33.89 Bn |
| Dec 31, 2014 | 34.30 Bn |
| Sep 30, 2014 | 34.73 Bn |
| Jun 30, 2014 | 35.21 Bn |
| Mar 31, 2014 | 38.70 Bn |
| Dec 31, 2013 | 38.76 Bn |
| Sep 30, 2013 | 26.40 Bn |
| Jun 30, 2013 | 22.94 Bn |
| Mar 31, 2013 | 22.95 Bn |
| Dec 31, 2012 | 23.09 Bn |
| Sep 30, 2012 | 22.84 Bn |
| Dec 31, 2011 | 21.28 Bn |
| Mar 31, 2010 | 20.56 Bn |
| Dec 31, 2009 | 20.70 Bn |
| Sep 30, 2009 | 20.97 Bn |
| Jun 30, 2009 | 21.14 Bn |